Cancer cell therapy trial pulled before it started

This study was designed to test a new treatment called CD30-targeted CAR-T cells for people with lymphoma (a type of blood cancer) that had returned or stopped responding to standard therapy. The treatment involved taking a patient's own immune cells, engineering them to recognize and attack cancer cells with a protein called CD30, and infusing them back. However, the trial was withdrawn before enrolling any participants, so no results are available.